Perdicchio, 2015 - Google Patents
Effects of sialic acids in immunityPerdicchio, 2015
View PDF- Document ID
- 18189438714413816929
- Author
- Perdicchio M
- Publication year
External Links
Snippet
Innate immune cells play a crucial role in the immune response against tumors. Particularly, dendritic cells (DCs), macrophages and NK cells are involved in the first phase of the process known as cancer immunoediting, where these cells detect the presence of a …
- 125000005629 sialic acid group 0 title abstract description 74
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11666660B2 (en) | Glycan-dependent immunotherapeutic molecules | |
| Singh et al. | Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation | |
| Ardolino et al. | Cytokine therapy reverses NK cell anergy in MHC-deficient tumors | |
| CA3135531A1 (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
| EP2185586B1 (en) | Immune modulation via c-type lectin | |
| Altman et al. | Antitumor responses of invariant natural killer T cells | |
| Li et al. | Identification of C‐glycoside analogues that display a potent biological activity against murine and human invariant natural killer T cells | |
| US20220001031A1 (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
| DK1569660T3 (en) | C-TYPE LECTIN BINDING MOLECULES, IDENTIFICATION AND APPLICATIONS THEREOF. | |
| US20220378824A1 (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
| Hömberg et al. | CD40‐independent natural killer‐cell help promotes dendritic cell vaccine‐induced T‐cell immunity against endogenous B‐cell lymphoma | |
| Kim et al. | Mycobacterium tuberculosis MmsA, a novel immunostimulatory antigen, induces dendritic cell activation and promotes Th1 cell-type immune responses | |
| Perdicchio | Effects of sialic acids in immunity | |
| Gupta et al. | DC-SIGN family of receptors | |
| Bediako et al. | SAP is required for the development of innate phenotype in H2-M3–restricted Cd8+ T cells | |
| Lyu et al. | NKT cells—a generalist in disease treatment and a new key to unlock immunotherapy | |
| Huang | Drug Design Strategies for Modulating Immune Activity for the Treatment of Autoimmune Diseases and Cancer | |
| Eberhardt et al. | Signaling and transcriptional Regulation in Immune Cells | |
| Spadafora | Immunogenic properties of differentially activated Dendritic Cells | |
| KR20250023513A (en) | Improved glycan-dependent immunotherapy bispecific fusion protein and chimeric antigen receptor | |
| KR20250036973A (en) | An improved glycan-dependent immunotherapeutic bispecific protein with a longer half-life | |
| Moon | Engineering homing properties of cancer-specific T lymphocytes in adoption cell therapy | |
| JP2025520404A (en) | Improved bispecific proteins with longer half-lives for glycan-dependent immunotherapy | |
| Benam | Characterisation of expression and function of respiratory epithelial CD1d | |
| Singh | Glycan-Lectin duet, Novel strategies for DC-targeting |